BioLife Solutions, Inc.
BioLife Solutions, Inc.
Your view on BLFS
Overview
What the company does, where it operates, and who runs it.
About BioLife Solutions, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Roderick de Greef
- Headquarters
- 3303 Monte Villa Parkway, Bothell, WA, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Roderick de Greef
- Headquarters
- 3303 Monte Villa Parkway, Bothell, WA, US
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.
The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services.
It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioLife Solutions, Inc., and the rating behind it. BLFS last traded at $34.95, 34.1× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioLife Solutions, Inc.. Starting points for BioLife Solutions, Inc.: P/E 34.1, EPS $1.03, beta 1.92 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioLife Solutions, Inc.. BioLife Solutions, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioLife Solutions, Inc.. Trailing twelve-month EPS for BioLife Solutions, Inc. stands at $1.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioLife Solutions, Inc.. BioLife Solutions, Inc. has reported as a listed company since 1989. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioLife Solutions, Inc. valued side by side against its closest peers. BioLife Solutions, Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioLife Solutions, Inc., and how their positions are changing. At a $1.71B market value, institutional positions materially move BioLife Solutions, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioLife Solutions, Inc. executives and directors. Shares of BioLife Solutions, Inc. have traded between $19.10 and $29.62 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioLife Solutions, Inc.. BioLife Solutions, Inc. is a $1.71B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioLife Solutions, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioLife Solutions, Inc.. Coverage tracks BioLife Solutions, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.